sodium nitriteWhat was measured
Measured, with no finding
290 endpoints
Show what was measuredHide what was measured
forearm blood flow and unstressed venous volume (venodilation) during brachial artery nitrite infusion 0.31 to 7.8 umol/min; venous plasma nitrite and protein-bound NO; compared between healthy volunteers and heart failure patients, both infused, no non-nitrite control arm
increases, forearm blood flow rose in CHF patients at infusion rates that did not change it in normal subjects (ANOVA F = 5.5), p = 0.02, n = 41
Not recorded as a finding: another reason, stated per paper
Forearm blood flow (FBF) increased markedly in CHF patients at NO₂⁻ infusion rates which induced no changes in normal subjects (ANOVA: F = 5.5; P = 0.02).
PMID 23472879 · one of two readings recorded this
forearm blood flow (FBF)
increases, p = 0.02, n = 41
Forearm blood flow (FBF) increased markedly in CHF patients at NO₂⁻ infusion rates which induced no changes in normal subjects (ANOVA: F = 5.5; P = 0.02)
PMID 23472879 · one of two readings recorded this
plasma protein-bound NO concentration at baseline
decreases, n = 41
Plasma protein-bound NO concentrations were lower in CHF patients than normal subjects at baseline
PMID 23472879 · one of two readings recorded this
unstressed venous volume (UVV)
increases, p = 0.01, n = 41
Unstressed venous volume (UVV) increased even with the lowest NO₂⁻ infusion rate in all subjects (indicating venodilation), with CHF patients being relatively hyporesponsive compared with normal subjects (ANOVA: F = 6.2; P = 0.01)
PMID 23472879 · one of two readings recorded this
venous blood pH and oxygen concentration
no effect, n = 41
There were no differences in venous blood pH or oxygen concentration between groups or during NO₂⁻ infusion
PMID 23472879 · one of two readings recorded this
venous plasma NO₂⁻ concentration at baseline
decreases, n = 41
Venous plasma NO₂⁻ concentrations were lower in CHF patients at baseline, and rose substantially less with NO₂⁻ infusion, without incremental oxidative generation of nitrate, consistent with accelerated clearance in these patients
PMID 23472879 · one of two readings recorded this
area at risk, mean (SD)
no effect
Mean (SD) | 33.1 (15.8) | 32.4 (14.1)
PMID 24639423 · one of two readings recorded this
area at risk, median
no effect
Median (25th, 75th) | 31 (21, 44) | 32.5 (22.5, 42)
PMID 24639423 · one of two readings recorded this
area at risk (T2), mean (SD)
no effect
Mean (SD) | 36.1 (24.8) | 38.1 (16.9)
PMID 24639423 · one of two readings recorded this
area at risk (T2), median
no effect
Median (25th, 75th) | 33 (19, 46) | 39 (26,51)
PMID 24639423 · one of two readings recorded this
blood methaemoglobin 10 min after study medication
increases, p = 0.005, n = 17
Blood methaemoglobin levels were similar in the nitrite vs. placebo groups at baseline (0.52 ± 0.08 vs. 0.59 ± 0.04%), were higher at 10 min following study medication (0.66 ± 0.12 vs. 0.57 ± 0.05; P = 0.005) and similar in both groups at 2 h
PMID 24639423 · one of two readings recorded this
blood methaemoglobin at baseline
no effect, n = 17
Blood methaemoglobin levels were similar in the nitrite vs. placebo groups at baseline (0.52 ± 0.08 vs. 0.59 ± 0.04%), were higher at 10 min following study medication (0.66 ± 0.12 vs. 0.57 ± 0.05; P = 0.005) and similar in both groups at 2 h
PMID 24639423 · one of two readings recorded this
CK AUC, mean (SD)
no effect, p = 0.79
Mean (SD) | 67 019 (42 446) | 59 574 (48 337) | 5766 (−8695, 20 288); 0.79
PMID 24639423 · one of two readings recorded this
final infarct size at 6 months, effect
no effect, p = 0.19, n = 118
Final infarct size at 6 months | n = 63 | n = 55 | −1.7 (−3.2, 5.5); 0.19
PMID 24639423 · one of two readings recorded this
final infarct size at 6 months, mean (SD)
no effect
Mean (SD) | 13.3 (8.7) | 15.0 (9.7)
PMID 24639423 · one of two readings recorded this
final infarct size at 6 months, median
no effect, n = 118
These data in 118 patients (63 in the nitrite group and 55 in the placebo group) did not differ significantly between the nitrite and placebo groups (median 12.0 vs. 14.0%)
PMID 24639423 · one of two readings recorded this
infarct size at 6–8 days (5-SD) adjusted for AAR (T2)
no effect, p = 0.92
There was no significant difference in infarct size (5-SD technique) using AAR (T2) as a covariate between the nitrite and placebo groups (effect size +0.1% 95% CI −2.5, +2.8; P = 0.92)
PMID 24639423 · one of two readings recorded this
infarct size at 6–8 days (5-SD), mean (SD)
no effect, p = 0.92
Mean (SD) | 14.5 (10.5) | 14.7 (11.2) | 0.1 (−2.5, 2.8); 0.92
PMID 24639423 · one of two readings recorded this
infarct size at 6–8 days (5-SD), median
no effect
Median (25th, 75th) | 12 (6, 20) | 11.5 (7, 22)
PMID 24639423 · one of two readings recorded this
infarct size at 6-8 days by cardiac MRI late gadolinium enhancement, percent of LV mass (primary endpoint)
no effect, difference -0.7% (95% CI: -2.2, +0.7; P = 0.30), p = 0.3
Not recorded as a finding: no outcome node for CMR infarct size
The median infarct size was 22% in the nitrite and 20% in the placebo groups [difference −0.7% (95% CI: −2.2, +0.7; P = 0.30)] (Table 2).
PMID 24639423 · one of two readings recorded this
infarct size at 6–8 days (LGE, CMR), mean (SD)
no effect, p = 0.3
Mean (SD) | 22.9 (13.5) | 23.1 (13.2) | −0.7 (−2.2, 0.7); 0.30
PMID 24639423 · one of two readings recorded this
infarct size at 6–8 days (LGE, CMR), median
no effect, p = 0.3, n = 173
The median infarct size was 22% in the nitrite and 20% in the placebo groups [difference −0.7% (95% CI: −2.2, +0.7; P = 0.30)]
PMID 24639423 · one of two readings recorded this
infarct size at 6–8 days treatment effect
no effect, p = 0.46
AAR ≤40% | −1.2 (−5.3, 3.0); 0.46
PMID 24639423 · one of two readings recorded this
infarct size at 6–8 days treatment effect
no effect, p = 0.13
Anterior | −1.9 (−5.1, 1.4); 0.13
PMID 24639423 · one of two readings recorded this
infarct size at 6–8 days treatment effect
decreases, p = 0.041
Diabetics | −4.5 (−8.8, −0.2); 0.041
PMID 24639423 · one of two readings recorded this
infarct size at 6–8 days treatment effect
no effect, p = 0.07
Early PCI | 2.9 (−1.3, 7.1); 0.070
PMID 24639423 · one of two readings recorded this
infarct size at 6–8 days treatment effect
no effect, p = 0.62
Interaction | −1.4 (−8.8, 6.0); 0.62
PMID 24639423 · one of two readings recorded this
infarct size at 6–8 days treatment effect
no effect, p = 0.067
Interaction | −4.3 (−8.9, 0.3); 0.067
PMID 24639423 · one of two readings recorded this
infarct size at 6–8 days treatment effect
no effect, p = 0.24
Interaction | −1.9 (−5.9, 2.2); 0.24
PMID 24639423 · one of two readings recorded this
infarct size at 6–8 days treatment effect
no effect, p = 0.94
Interaction | −0.1 (−3.9, 3.7); 0.94
PMID 24639423 · one of two readings recorded this
infarct size at 6–8 days treatment effect
unclear, p = 0.012
Interaction | 4.6 (−0.1, 9.3); 0.012
PMID 24639423 · one of two readings recorded this
infarct size at 6–8 days treatment effect
decreases, p = 0.045
Late PCI | −1.7 (−3.8, 0.5); 0.045
PMID 24639423 · one of two readings recorded this
infarct size at 6–8 days treatment effect
no effect, p = 0.47
Microvascular obstruction | −0.7 (−3.4, 1.9); 0.47
PMID 24639423 · one of two readings recorded this
infarct size at 6–8 days treatment effect
no effect, p = 0.54
No microvascular obstruction | −0.6 (−3.3, 2.1); 0.54
PMID 24639423 · one of two readings recorded this
infarct size at 6–8 days treatment effect
no effect, p = 0.77
Non-diabetics | −0.2 (−1.8, 1.3); 0.77
PMID 24639423 · one of two readings recorded this
infarct size at 6–8 days treatment effect
no effect, p = 0.97
Other site | 0.0 (−2.4, 2.4); 0.97
PMID 24639423 · one of two readings recorded this
LV volume change (delta, labelled LVDV), mean (SD)
no effect, p = 0.66
Mean (SD) | 9 (25) | 6 (24) | 2.0 (−7.2, 11.2); 0.66
PMID 24639423 · one of two readings recorded this
LVEDV at 6–8 days, effect
no effect, p = 0.58, n = 159
LVEDV (mL) at 6–8 days | n = 75 | n = 84 | −3.5 (−16.3, 9.2); 0.58
PMID 24639423 · one of two readings recorded this
LVEDV at 6–8 days, mean (SD)
no effect
Mean (SD) | 159 (41) | 162 (40)
PMID 24639423 · one of two readings recorded this
LVEDV at 6 months, mean (SD)
no effect, p = 0.5
Mean (SD) | 159 (42) | 165 (37) | −5.0 (−19.8, 9.8); 0.50
PMID 24639423 · one of two readings recorded this
LVEDV change from 6–8 days to 6 months (delta), mean (SD)
no effect, p = 0.82
Mean (SD) | −1 (29) | −3 (32) | 1.3 (−10.1, 12.6); 0.82
PMID 24639423 · one of two readings recorded this
LVEF at 6–8 days, mean (SD)
no effect, p = 0.34
Mean (SD) | 48 (11) | 50 (18) | −2.3 (−7.1, 2.4); 0.34
PMID 24639423 · one of two readings recorded this
LVEF at 6 months, mean (SD)
no effect, p = 0.72
Mean (SD) | 53 (9) | 53 (9) | −0.6 (−3.9, 2.7); 0.72
PMID 24639423 · one of two readings recorded this
LVEF change from 6–8 days to 6 months (delta), mean (SD)
no effect, p = 0.57
Mean (SD) | −5 (8) | −3 (22) | −1.7 (−7.6, 4.2); 0.57
PMID 24639423 · one of two readings recorded this
LVESV at 6–8 days, mean (SD)
no effect, p = 0.93
Mean (SD) | 85 (36) | 85 (32) | 0.5 (−10.4,11.3); 0.93
PMID 24639423 · one of two readings recorded this
LVESV at 6 months, mean (SD)
no effect, p = 0.63
Mean (SD) | 75 (31) | 78 (28) | −2.7 (−13.7,8.3); 0.63
PMID 24639423 · one of two readings recorded this
myocardial infarct size at 6-8 days, late gadolinium enhancement by CMR planimetry as percent of LV mass (primary)
no effect, difference -0.7% (95% CI -2.2, +0.7), p = 0.3
Not recorded as a finding: no outcome node for CMR infarct size
The median infarct size was 22% in the nitrite and 20% in the placebo groups [difference −0.7% (95% CI: −2.2, +0.7; P = 0.30)] (Table 2).
PMID 24639423 · one of two readings recorded this
plasma creatine kinase area under the curve over 72 h as infarct-size marker
+5766 arbitrary units (95% CI -8695, +20 288), p = 0.79
Not recorded as a finding: creatine-kinase node is serum CK activity as a marker of exercise-induced muscle damage, not 72-h AUC after myocardial infarction
The effect size was −125 arbitrary units (95% CI: −1139, +888 units; P = 0.81) for Troponin I, and +5766 arbitrary units (95% CI: −8695, +20 288 units; P = 0.79) for CK.
PMID 24639423 · one of two readings recorded this
plasma creatine kinase AUC, effect size
no effect, p = 0.79
The effect size was −125 arbitrary units (95% CI: −1139, +888 units; P = 0.81) for Troponin I, and +5766 arbitrary units (95% CI: −8695, +20 288 units; P = 0.79) for CK
PMID 24639423 · one of two readings recorded this
plasma nitrite 5 min after ceasing infusion
increases, p = 0.008, n = 17
Plasma nitrite [mean (SD), µmol/L] was similar at baseline [0.76 (0.14) vs. 0.73 (0.08)] but higher in the nitrite group 5 min after ceasing infusion [1.42 (0.96) vs. 0.18 (0.08); P = 0.008]
PMID 24639423 · one of two readings recorded this
plasma nitrite at baseline
no effect, n = 17
Plasma nitrite [mean (SD), µmol/L] was similar at baseline [0.76 (0.14) vs. 0.73 (0.08)] but higher in the nitrite group 5 min after ceasing infusion [1.42 (0.96) vs. 0.18 (0.08); P = 0.008]
PMID 24639423 · one of two readings recorded this
plasma total creatine kinase area under the curve over 72 h as infarct-size biomarker
no effect, +5766 arbitrary units (95% CI: -8695, +20 288 units; P = 0.79), p = 0.79
Not recorded as a finding: creatine-kinase node is serum CK activity as a marker of exercise-induced muscle damage; this is a 72-h AUC for myocardial infarct size, a different contrast
The effect size was −125 arbitrary units (95% CI: −1139, +888 units; P = 0.81) for Troponin I, and +5766 arbitrary units (95% CI: −8695, +20 288 units; P = 0.79) for CK.
PMID 24639423 · one of two readings recorded this
plasma troponin I AUC, effect size
no effect, p = 0.81
The effect size was −125 arbitrary units (95% CI: −1139, +888 units; P = 0.81) for Troponin I, and +5766 arbitrary units (95% CI: −8695, +20 288 units; P = 0.79) for CK
PMID 24639423 · one of two readings recorded this
serious adverse events during safety follow-up, 19 of 146 nitrite versus 25 of 134 placebo
21 events in 19 of 146 (13%) nitrite versus 29 events in 25 of 134 (19%) placebo
Not recorded as a finding: sentence gives counts with no direction word or between-arm test, so direction is not in words for the serious-adverse-event-incidence node
There were 21 events in 19 of 146 participants (13%) in the nitrite group, 29 events in 25 of 134 participants in the (19%) placebo group.
PMID 24639423 · one of two readings recorded this
troponin AUC, mean (SD)
no effect, p = 0.81
Mean (SD) | 3734 (3091) | 3807 (3262) | −125 (−1139, 888); 0.81
PMID 24639423 · one of two readings recorded this
FENO fold over pre-dose baseline across dose cohorts
increases
Values averaged across all dose cohorts were 4- to 5-fold over pre-dose baseline on both days 1 and 6
PMID 25421879 · one of two readings recorded this
fraction exhaled nitric oxide (FENO), pre-dose to post-dose, day 1
increases, n = 18
Mean FENO increased from 16.1 to 68.7 ppb on day 1 (4.3-fold increase) and from 14.8 to 84.3 ppb on day 6 (5.7-fold increase)
PMID 25421879 · one of two readings recorded this
fraction exhaled nitric oxide (FENO), pre-dose to post-dose, day 6
increases, n = 18
Mean FENO increased from 16.1 to 68.7 ppb on day 1 (4.3-fold increase) and from 14.8 to 84.3 ppb on day 6 (5.7-fold increase)
PMID 25421879 · one of two readings recorded this
maximal venous methemoglobin
increases
Maximal MetHb concentrations did not exceed 3.0 % in any subject, nor were any changes in SaO2 observed in any subject in the three trials presented
PMID 25421879 · one of two readings recorded this
mean arterial pressure after single inhaled nebulized sodium nitrite in healthy subjects (study CS01, 176 mg cohort)
decreases, n = 6
Not recorded as a finding: no placebo or no-nitrite control arm in the open-label single-ascending-dose study; change is within-subject and a dose-limiting toxicity description, not a between-arm contrast
When averaged across the six subjects in this cohort, maximal decreases in MAP were 13 mmHg, which was associated with a mean heart rate increase of 12 bpm.
PMID 25421879 · one of two readings recorded this
plasma N-desmethyl sildenafil trough concentration
no effect, n = 4
N-desmethyl sildenafil (ng/mL)c | 9.75 (7.51) | 8.85 (4.83) | 9.89 (6.61) | 11.6 (10.9) | 8.09 (1.31) | 9.67
PMID 25421879 · one of two readings recorded this
plasma sildenafil trough concentration
no effect, n = 4
Sildenafil (ng/mL)c | 16.5 (11.8) | 14.4 (8.3) | 18.3 (13.9) | 17.5 (7.7) | 14.6 (8.6) | 10.7
PMID 25421879 · one of two readings recorded this
S-nitrosothiol (R-SNO) maximal concentration, blood, day 6
the maximal R-SNO concentrations at the MTD dosage level of 90 mg on study day 6 were 0.026 ± 0.005 µmol/L (mean ± standard deviation) in plasma vs. 0.274 ± 0.058 µmol/L in blood
PMID 25421879 · one of two readings recorded this
S-nitrosothiol (R-SNO) maximal concentration, plasma, day 6
the maximal R-SNO concentrations at the MTD dosage level of 90 mg on study day 6 were 0.026 ± 0.005 µmol/L (mean ± standard deviation) in plasma vs. 0.274 ± 0.058 µmol/L in blood
PMID 25421879 · one of two readings recorded this
6-month CMR infarct size vs P-selectin expression (ADP) at 6 months correlation
increases, p = 0.002
6 month CMR infarct size positively associated with both P-selectin expression (r=0.401, p=0.002, Figure 5E) and platelet aggregation (r=0.344, p=0.007, Figure 5F) at 6 months in response to ADP
PMID 25512434 · one of two readings recorded this
6-month CMR infarct size vs platelet aggregation (ADP) at 6 months correlation
increases, p = 0.007
6 month CMR infarct size positively associated with both P-selectin expression (r=0.401, p=0.002, Figure 5E) and platelet aggregation (r=0.344, p=0.007, Figure 5F) at 6 months in response to ADP
PMID 25512434 · one of two readings recorded this
ADP-induced P-selectin expression at baseline
no effect
unstimulated mean ± SD P-selectin expression in the whole cohort was 8.9±4.6% and 7.9±4.8% and ADP-induced P-selectin expression was 47.2±18.9 and 46.9±18.2 in the placebo and nitrite-treated groups respectively
PMID 25512434 · one of two readings recorded this
adverse clinical events in first 48 hours after reperfusion
no effect, n = 80
During the first 48 hours after reperfusion, 7 adverse clinical events were recorded in the control group compared to 3 in the nitrite group (Table 2)
PMID 25512434 · one of two readings recorded this
CMR area at risk vs APPROACH score correlation
increases, p = 0.01
The CMR-assessed AAR was associated with both angiographic risk scores (APPROACH: r=0.678, p<0.01, BARI: r=0.541, p<0.01, Online Figure II)
PMID 25512434 · one of two readings recorded this
CMR area at risk vs BARI score correlation
increases, p = 0.01
The CMR-assessed AAR was associated with both angiographic risk scores (APPROACH: r=0.678, p<0.01, BARI: r=0.541, p<0.01, Online Figure II)
PMID 25512434 · one of two readings recorded this
CMR-determined infarct size
decreases, p = 0.03
there was a significant decrease in CMR-determined myocardial infarct size (15.31 (12.36-18.27) vs 20.08 (16.72-23.43), p=0.03)
PMID 25512434 · one of two readings recorded this
CMR infarct size vs creatine kinase correlation
increases, p = 0.01
CMR-assessed infarct size was positively associated with cardiac biomarkers (CK, r=0.770, p<0.01: troponin T, r=0.787, p<0.01, Online Figure I)
PMID 25512434 · one of two readings recorded this
CMR infarct size vs troponin T correlation
increases, p = 0.01
CMR-assessed infarct size was positively associated with cardiac biomarkers (CK, r=0.770, p<0.01: troponin T, r=0.787, p<0.01, Online Figure I)
PMID 25512434 · one of two readings recorded this
infarct size by area under the curve of serum creatine kinase release over two days after intracoronary sodium nitrite in STEMI (primary); troponin T AUC, CMR infarct size, myocardial salvage index, 1-year MACE (secondary)
no effect, median CK AUC 56,398 (nitrite) vs 48,195 (control) arbitrary units, p = 0.92, n = 80
Not recorded as a finding: a node exists but the paper states a different instrument or population
There was no evidence of a difference in the CK AUC between the nitrite and control groups, with a median of 56,398 arbitrary units (IQR: 31185 to 83,531) in the nitrite group versus 48,195 (IQR: 27,726 to 82,841) in the control group (p=0.92).
PMID 25512434 · one of two readings recorded this
infarct size by area under the curve of serum creatine kinase release over two days after primary PCI (primary endpoint); also troponin T AUC, CMR infarct size, myocardial salvage index, MACE at 1 year
no effect, median CK AUC 56,398 vs 48,195 arbitrary units, nitrite vs control, p = 0.92
Not recorded as a finding: this platform holds no node for the endpoint
There was no evidence of a difference in the CK AUC between the nitrite and control groups, with a median of 56,398 arbitrary units (IQR: 31185 to 83,531) in the nitrite group versus 48,195 (IQR: 27,726 to 82,841) in the control group (p=0.92).
PMID 25512434 · one of two readings recorded this
infarct size, CK and troponin T AUC
no effect, n = 9
No evidence of a difference in infarct size assessed by CK or troponin T AUC was seen in the patients with TIMI flow >1 treated with nitrite compared to placebo
PMID 25512434 · one of two readings recorded this
infarct size, creatine kinase AUC
no effect, p = 0.92, n = 80
There was no evidence of a difference in the CK AUC between the nitrite and control groups, with a median of 56,398 arbitrary units (IQR: 31185 to 83,531) in the nitrite group versus 48,195 (IQR: 27,726 to 82,841) in the control group (p=0.92)
PMID 25512434 · one of two readings recorded this
infarct size, creatine kinase AUC
decreases, p = 0.03, n = 66
with a median of 44,608 arbitrary units (IQR: 27,535 to 64,848) in the nitrite group versus 55,666 (IQR: 41,591 to 93,659) in the control group (p=0.030)
PMID 25512434 · one of two readings recorded this
infarct size reduction by CK AUC, relative
decreases, n = 66
This represents a 19% reduction in infarct size
PMID 25512434 · one of two readings recorded this
infarct size, troponin T AUC
no effect, n = 80
The median AUC for troponin T release was 140,782 arbitrary units (IQR, 84,949 to 218,133) in the nitrite group and 136,412 arbitrary units (IQR: 70,045 to 239,483) in the control group
PMID 25512434 · one of two readings recorded this
infarct size, troponin T AUC
no effect, p = 0.16, n = 66
The median AUC for troponin T release was 131,410 (IQR: 71,337 to 183,452) in the nitrite group and 176,492 (IQR: 89,831 to 245,094) in the control group (p=0.16)
PMID 25512434 · one of two readings recorded this
major adverse cardiac events (MACE) at 1 year
decreases, p = 0.04, n = 80
1 year after infarction, 6 MACE events were recorded in the control group compared to 1 in the nitrite group (p=0.04, see Table 2)
PMID 25512434 · one of two readings recorded this
microvascular obstruction (MVO) incidence
decreases
associated with a reduction in MVO (37% vs 72.4%) in the nitrite-treated patients
PMID 25512434 · one of two readings recorded this
myocardial salvage index (CMR)
increases, p = 0.05, n = 68
myocardial salvage index was improved in the nitrite group compared to placebo, although this difference fell on the borders of conventional statistical significance (p=0.05; Figure 2A)
PMID 25512434 · one of two readings recorded this
myocardial salvage index (CMR)
increases, p = 0.002
an increased myocardial salvage index (0.56 (0.50-0.62) vs 0.43 (0.37-0.49), p=0.002)
PMID 25512434 · one of two readings recorded this
systolic blood pressure decrease >10% within 10 minutes
Following administration of nitrite 45% of patients developed a >10% decrease in systolic blood pressure (within 10 minutes)
PMID 25512434 · one of two readings recorded this
unstimulated P-selectin expression at baseline
no effect
unstimulated mean ± SD P-selectin expression in the whole cohort was 8.9±4.6% and 7.9±4.8% and ADP-induced P-selectin expression was 47.2±18.9 and 46.9±18.2 in the placebo and nitrite-treated groups respectively
PMID 25512434 · one of two readings recorded this
arterial elastance
decreases, p = 0.002, n = 17
Arterial elastance fell by 18% from 1.95±0.71 to 1.60±0.53 mm Hg/mL (P=0.002; Table 2)
PMID 25838311 · one of two readings recorded this
arterial oxygen saturation
no effect, n = 25
Mean arterial oxygen saturation remained unchanged at either infusion rate
PMID 25838311 · one of two readings recorded this
cardiac output (CO)
increases, n = 17
CO significantly increased by 13% and SV significantly increased by 14%
PMID 25838311 · one of two readings recorded this
change in LV stroke volume by baseline SVR (above vs below mean)
no effect, p = 0.3, n = 17
There was no significant difference in the change in LV SV between these 2 groups (9.9+8.5 versus 5.1+8.8 mL; P=0.3)
PMID 25838311 · one of two readings recorded this
correlation of change in SV with change in estimated TSG
increases, p = 0.003, n = 17
the change in SV during 50 μg/kg/min nitrite infusion was significantly correlated with the change in estimated TSG (r=0.67; P=0.003)
PMID 25838311 · one of two readings recorded this
estimated trans-septal gradient (TSG)
increases, p = 0.005, n = 11
Estimated TSG increased by 3.6 mm Hg in the high PCWP subgroup (from 11.9±6.8 to 15.5±4.7 mm Hg; P=0.005)
PMID 25838311 · one of two readings recorded this
estimated trans-septal gradient (TSG)
increases, n = 17
Consequently, estimated TSG significantly increased by a mean of 3 mm Hg
PMID 25838311 · one of two readings recorded this
heart rate
no effect, n = 25
As shown in Table 2, there was no statistically significant change in heart rate at either infusion rate
PMID 25838311 · one of two readings recorded this
mean arterial blood pressure (MABP) change from pre-infusion baseline during 5-minute IV NaNO2 infusion at 10 or 50 ug/kg/min in heart failure patients; also stroke volume, pulmonary and systemic vascular resistance, plasma nitrite
decreases, MABP decreased by a mean of 4 mm Hg at 50 ug/kg/min; not significant at 10 ug/kg/min, p = 0.004, n = 17
Not recorded as a finding: the result compares a group with itself, not with a control
10 μg/kg/min NaNO2 infusion did not significantly affect MABP, whereas in contrast 50 μg/kg/min of NaNO2 infusion modestly but significantly decreased MABP by a mean of 4 mm Hg (P<0.004).
PMID 25838311 · one of two readings recorded this
mean arterial blood pressure (MABP) change from pre- to post-infusion during 5-minute IV NaNO2 at 10 or 50 ug/kg/min, invasive hemodynamics by right heart catheterization
decreases, 50 ug/kg/min: mean fall of 4 mm Hg from baseline; 10 ug/kg/min not significant, p = 0.004, n = 25
Not recorded as a finding: the result compares a group with itself, not with a control
10 μg/kg/min NaNO2 infusion did not significantly affect MABP, whereas in contrast 50 μg/kg/min of NaNO2 infusion modestly but significantly decreased MABP by a mean of 4 mm Hg (P<0.004).
PMID 25838311 · one of two readings recorded this
mean arterial blood pressure (MABP)
no effect, n = 8
10 μg/kg/min NaNO2 infusion did not significantly affect MABP
PMID 25838311 · one of two readings recorded this
mean arterial blood pressure (MABP)
decreases, p = 0.004, n = 17
whereas in contrast 50 μg/kg/min of NaNO2 infusion modestly but significantly decreased MABP by a mean of 4 mm Hg (P<0.004)
PMID 25838311 · one of two readings recorded this
methemoglobin
increases, n = 25
As shown in Table 3, a modest dose-dependent increase in methemoglobin was observed after 10 and 50 μg/kg/min of sodium nitrite
PMID 25838311 · one of two readings recorded this
plasma nitrite, nitrate and RXNO
increases, n = 17
50 μg/kg/min NaNO2 infusion significantly increased all measured NO metabolites from baseline
PMID 25838311 · one of two readings recorded this
plasma nitrite
increases, n = 8
10 μg/kg/min NaNO2 infusion did not significantly alter plasma RXNO or plasma nitrate concentrations but significantly increased plasma nitrite
PMID 25838311 · one of two readings recorded this
pulmonary capillary wedge pressure (PCWP)
no effect, n = 17
As shown in Table 2, in the 50 μg/kg/min group, there was a significant reduction in mean RAP by 40% and PCWP fell by 7% (nonsignificant)
PMID 25838311 · one of two readings recorded this
pulmonary vascular resistance (PVR)
decreases, p = 0.03, n = 17
As shown in Table 2, 50 μg/kg/min of NaNO2 infusion significantly decreased PVR by 29% (P=0.03), and systemic vascular resistance fell by 12% (P=0.01; Table 2)
PMID 25838311 · one of two readings recorded this
PVR and SVR
no effect, n = 8
Infusion of 10 μg/kg/min NaNO2 infusion resulted in directionally similar effects, but these were not significant
PMID 25838311 · one of two readings recorded this
right atrial pressure (RAP)
decreases, n = 17
As shown in Table 2, in the 50 μg/kg/min group, there was a significant reduction in mean RAP by 40% and PCWP fell by 7% (nonsignificant)
PMID 25838311 · one of two readings recorded this
stroke volume (SV)
increases, p = 0.003, n = 11
In 11 patients with PCWP >15 mm Hg (mean 22.4±8.0 mm Hg), infusion of sodium nitrite at the higher concentration increased SV by 20% from 43.22±21.5 to 51.84±23.6 mL (P=0.003)
PMID 25838311 · one of two readings recorded this
stroke volume (SV)
increases, n = 8
10 μg/kg/min NaNO2 infusion resulted in a significant increase in SV by 15.5%, but the increase in CO was not significant
PMID 25838311 · one of two readings recorded this
stroke volume (SV)
increases, n = 17
CO significantly increased by 13% and SV significantly increased by 14%
PMID 25838311 · one of two readings recorded this
systemic vascular resistance (SVR)
decreases, p = 0.01, n = 17
As shown in Table 2, 50 μg/kg/min of NaNO2 infusion significantly decreased PVR by 29% (P=0.03), and systemic vascular resistance fell by 12% (P=0.01; Table 2)
PMID 25838311 · one of two readings recorded this
body mass
no effect
Not recorded as a finding: Stated as unchanged within the same baseline-referenced (within-arm) sentence as the FMD finding; no between-arm contrast given.
Endothelial function, measured by brachial artery flow-mediated dilation, increased 45-60% vs. baseline (P < 0.10) without changes in body mass or blood lipids.
PMID 26607249 · one of two readings recorded this
aortic pulse wave velocity
no effect
Not recorded as a finding: Stated as unchanged with no stated comparator (baseline or placebo); insufficient to anchor a between-arm claim on CAT:outcome/carotid-femoral-pulse-wave-velocity.
Aortic pulse wave velocity was unchanged.
PMID 26607249 · both readings recorded this
Blood lipids (unspecified panel)
no effect
Not recorded as a finding: no_outcome_node - no specific lipid parameter (LDL, HDL, triglycerides, total cholesterol) is named, so this cannot be mapped to any single lipid outcome node
Endothelial function, measured by brachial artery flow-mediated dilation, increased 45-60% vs. baseline (P < 0.10) without changes in body mass or blood lipids.
PMID 26607249 · one of two readings recorded this
blood lipids
no effect
Not recorded as a finding: No specific lipid analyte named (no matching outcome node) and reported within the same baseline-referenced statement as the FMD finding, not a between-arm contrast.
Endothelial function, measured by brachial artery flow-mediated dilation, increased 45-60% vs. baseline (P < 0.10) without changes in body mass or blood lipids.
PMID 26607249 · one of two readings recorded this
brachial and carotid artery blood pressure
no effect
Not recorded as a finding: No specific setting/instrument distinguishing which blood-pressure node applies, and stated as unchanged with no between-arm contrast given.
Measures of carotid artery elasticity (ultrasound and applanation tonometry) improved (decreased β-stiffness index, increased cross-sectional compliance, P < 0.05) without changes in brachial or carotid artery blood pressure.
PMID 26607249 · both readings recorded this
carotid artery beta-stiffness index
decreases, decreased β-stiffness index, P < 0.05
Not recorded as a finding: No outcome node for carotid arterial beta-stiffness index, and no between-arm contrast is stated.
Measures of carotid artery elasticity (ultrasound and applanation tonometry) improved (decreased β-stiffness index, increased cross-sectional compliance, P < 0.05) without changes in brachial or carotid artery blood pressure.
PMID 26607249 · one of two readings recorded this
carotid artery cross-sectional compliance
increases, increased cross-sectional compliance, P < 0.05
Not recorded as a finding: No outcome node for carotid cross-sectional compliance, and no between-arm contrast is stated.
Measures of carotid artery elasticity (ultrasound and applanation tonometry) improved (decreased β-stiffness index, increased cross-sectional compliance, P < 0.05) without changes in brachial or carotid artery blood pressure.
PMID 26607249 · one of two readings recorded this
Carotid artery cross-sectional compliance
increases, increased cross-sectional compliance
Measures of carotid artery elasticity (ultrasound and applanation tonometry) improved (decreased β-stiffness index, increased cross-sectional compliance, P < 0.05) without changes in brachial or carotid artery blood pressure.
PMID 26607249 · one of two readings recorded this
Carotid artery β-stiffness index and cross-sectional compliance, by ultrasound and applanation tonometry
decreases, decreased β-stiffness index, increased cross-sectional compliance
Not recorded as a finding: no_outcome_node - no outcome in the list corresponds to carotid β-stiffness index or cross-sectional compliance
Measures of carotid artery elasticity (ultrasound and applanation tonometry) improved (decreased β-stiffness index, increased cross-sectional compliance, P < 0.05) without changes in brachial or carotid artery blood pressure.
PMID 26607249 · one of two readings recorded this
Carotid artery β-stiffness index
decreases, decreased β-stiffness index
Measures of carotid artery elasticity (ultrasound and applanation tonometry) improved (decreased β-stiffness index, increased cross-sectional compliance, P < 0.05) without changes in brachial or carotid artery blood pressure.
PMID 26607249 · one of two readings recorded this
endothelial function, brachial artery flow-mediated dilation
increases, increased 45-60% vs. baseline
Not recorded as a finding: Reported as percent change vs. baseline (within-arm), not a between-arm contrast against placebo; CAT:outcome/flow-mediated-dilation would need a between-group finding for a claim.
Endothelial function, measured by brachial artery flow-mediated dilation, increased 45-60% vs. baseline (P < 0.10) without changes in body mass or blood lipids.
PMID 26607249 · both readings recorded this
Correlation of baseline PVR with PVR reduction after nitrite
unclear, p = 0.005
subjects with higher PVR displayed greater PVR reductions with nitrite measured at baseline (r2=0.56, p=0.005)
PMID 27458234 · one of two readings recorded this
Correlation of plasma nitrite level with reduction in exercise PCWP
unclear, p = 0.13
Higher NO2 levels tended to be associated with greater reductions in exercise PCWP (r= −0.44, p=0.13)
PMID 27458234 · one of two readings recorded this
Correlation of plasma nitrite level with reduction in PA systolic pressure
unclear, p = 0.11
and PA systolic pressure (r= −0.46, p=0.11)
PMID 27458234 · one of two readings recorded this
Correlation of PVR with PVR reduction after nitrite
unclear, p = 0.001
and during exercise (r2=0.68, p<0.001)
PMID 27458234 · one of two readings recorded this
Exercise heart rate and systolic blood pressure
no effect, n = 26
Nitrite had no effect on exercise HR or systolic BP
PMID 27458234 · one of two readings recorded this
Exercise mean blood pressure
unclear, p = 0.07, n = 26
tended to reduce mean BP during exercise more than placebo (p=0.07, Table 4)
PMID 27458234 · one of two readings recorded this
Exercise pulmonary capillary wedge pressure (PCWP)
decreases, p = 0.022, n = 26
The primary endpoint of exercise PCWP was significantly improved with nitrite compared to placebo (adjusted mean 25±5 vs 31±6 mmHg, ANCOVA p=0.022; Table 4, Figure 2)
PMID 27458234 · one of two readings recorded this
Exercise PVR and PA compliance
no effect, n = 26
While there was no effect of nitrite on exercise PVR or PA compliance
PMID 27458234 · one of two readings recorded this
Exercise right atrial and PA mean pressures
decreases, n = 26
Nitrite decreased exercise RA and PA mean pressures compared to placebo
PMID 27458234 · one of two readings recorded this
Exercise systemic vascular resistance, VO2, CaO2 – CvO2, CI, SVI
no effect, n = 26
Nitrite had no effect on exercise systemic vascular resistance, VO2, CaO2 – CvO2, CI or SVI
PMID 27458234 · one of two readings recorded this
Methemoglobin change
no effect, p = 0.8, n = 26
Inhaled nitrite did not alter methemoglobin levels compared to placebo (+0.1±0.2 vs +0.1±0.3%, p=0.8)
PMID 27458234 · one of two readings recorded this
methemoglobin level change versus placebo, safety endpoint
no effect, +0.1±0.2 vs +0.1±0.3%, p=0.8, p = 0.8
Not recorded as a finding: no outcome node for methemoglobin
Inhaled nitrite did not alter methemoglobin levels compared to placebo (+0.1±0.2 vs +0.1±0.3%, p=0.8).
PMID 27458234 · one of two readings recorded this
methemoglobin level, safety endpoint
no effect, +0.1 +/- 0.2 vs +0.1 +/- 0.3% nitrite vs placebo, p = 0.8
Not recorded as a finding: no outcome node for blood methemoglobin
Inhaled nitrite did not alter methemoglobin levels compared to placebo (+0.1±0.2 vs +0.1±0.3%, p=0.8).
PMID 27458234 · one of two readings recorded this
pulmonary capillary wedge pressure during exercise (primary), invasive right heart catheterization
decreases, adjusted mean 25 +/- 5 vs 31 +/- 6 mmHg nitrite vs placebo, p = 0.022
Not recorded as a finding: no outcome node for pulmonary capillary wedge pressure
The primary endpoint of exercise PCWP was significantly improved with nitrite compared to placebo (adjusted mean 25±5 vs 31±6 mmHg, ANCOVA p=0.022; Table 4, Figure 2).
PMID 27458234 · one of two readings recorded this
pulmonary capillary wedge pressure during exercise, right heart catheterization (primary endpoint)
decreases, adjusted mean 25±5 vs 31±6 mmHg, ANCOVA p=0.022, p = 0.022
Not recorded as a finding: no outcome node for invasive pulmonary capillary wedge pressure
The primary endpoint of exercise PCWP was significantly improved with nitrite compared to placebo (adjusted mean 25±5 vs 31±6 mmHg, ANCOVA p=0.022; Table 4, Figure 2).
PMID 27458234 · one of two readings recorded this
Resting heart rate and blood pressure
no effect, n = 26
There was no effect of inhaled nitrite on heart rate or blood pressure at rest (Table 3)
PMID 27458234 · one of two readings recorded this
Resting pulmonary and systemic vascular resistance, VO2, CI, CaO2 – CvO2, SVI
no effect, n = 26
Nitrite had no effect on resting pulmonary or systemic vascular resistance, VO2, CI, CaO2 – CvO2, or SVI compared to placebo
PMID 27458234 · one of two readings recorded this
Resting right atrial pressure, PCWP, PA pressures and PA compliance
decreases, n = 26
as compared to placebo, inhaled nitrite reduced right atrial pressure, PCWP and PA pressures while improving PA compliance
PMID 27458234 · one of two readings recorded this
VE/VCO2 slope change from pre-study drug
no effect, p = 0.26, n = 26
VE/VCO2 slope tended to be lower following nitrite as compared to placebo (+1±4 vs +3±3 compared to pre-study drug, p=0.26)
PMID 27458234 · one of two readings recorded this
acute blood pressure lowering effect of increasing intravenous doses of nitrite in freely moving rats
decreases, nitrate attenuated the acute blood pressure lowering effects of nitrite
Not recorded as a finding: the intervention held more than the compound
Further confirming these results, we found that nitrate attenuated the acute blood pressure lowering effects of increasing doses of nitrite infused intravenously in freely moving rats.
PMID 28285190 · one of two readings recorded this
acute blood pressure lowering effect of intravenously infused nitrite doses in freely moving rats
decreases
Not recorded as a finding: the intervention held more than the compound
Further confirming these results, we found that nitrate attenuated the acute blood pressure lowering effects of increasing doses of nitrite infused intravenously in freely moving rats.
PMID 28285190 · one of two readings recorded this
acute blood pressure (mean arterial pressure) response to intravenous nitrite infusion, with/without nitrate, freely moving rats
decreases
Further confirming these results, we found that nitrate attenuated the acute blood pressure lowering effects of increasing doses of nitrite infused intravenously in freely moving rats.
PMID 28285190 · one of two readings recorded this
aortic accumulation of nitrogen-15-labeled nitrite (15N-nitrite) by UPLC-MS/MS, with/without nitrate
no effect
Nitrate exerted no effect on aortic accumulation of 15N-nitrite.
PMID 28285190 · one of two readings recorded this
aortic tissue accumulation of nitrogen-15-labeled nitrite (15N-nitrite)
no effect
Nitrate exerted no effect on aortic accumulation of 15N-nitrite.
PMID 28285190 · one of two readings recorded this
vascular relaxation response of aortic rings and perfused mesenteric arterial bed to nitrite, with/without nitrate
decreases
Both assays showed that nitrate attenuated the vascular responses to nitrite.
PMID 28285190 · one of two readings recorded this
vascular relaxation response to nitrite in aortic ring and mesenteric arterial bed preparations
decreases
Both assays showed that nitrate attenuated the vascular responses to nitrite.
PMID 28285190 · one of two readings recorded this
xanthine oxidoreductase (XOR)-mediated nitrite reductase kinetics (Michaelis constant for nitrite)
decreases, 3-fold increase in the Michaelis constant
Nitrate significantly shifted the Michaelis Menten saturation curve to the right, with a 3-fold increase in the Michaelis constant.
PMID 28285190 · one of two readings recorded this
xanthine oxidoreductase (XOR)-mediated nitrite reductase kinetics (Michaelis constant), with/without nitrate
decreases, 3-fold increase in the Michaelis constant
Nitrate significantly shifted the Michaelis Menten saturation curve to the right, with a 3-fold increase in the Michaelis constant.
PMID 28285190 · one of two readings recorded this
Baseline methemoglobin
Baseline methemoglobin levels were 0.76 ± 0.17 vs. 0.60 ± 0.2 respectively for nitrite and placebo groups
PMID 29175357 · one of two readings recorded this
mean arterial pressure and heart rate after IV sodium nitrite 1 mg or 9.6 mg vs placebo (automated cuff, telemetry); whole blood methemoglobin by cooximetry; blood nitrite by triiodide chemiluminescence
Not recorded as a finding: no estimate is reported anywhere
Neither the 1 mg or 9.6 mg nitrite dose resulted in a significant decrease in MAP or increase in heart rate.
PMID 29175357 · one of two readings recorded this
Mean arterial pressure and heart rate
no effect
Neither the 1 mg or 9.6 mg nitrite dose resulted in a significant decrease in MAP or increase in heart rate
PMID 29175357 · one of two readings recorded this
Methemoglobin after infusion
no effect
changed minimally in response to nitrite or placebo infusion (0.92 ± 0.33 vs. 0.70 ± 0.26)
PMID 29175357 · one of two readings recorded this
Plasma cGMP
unclear, n = 3
Only one patient receiving nitrite had an increase in cGMP (patient B3; Figure 3C)
PMID 29175357 · one of two readings recorded this
Plasma S-nitrosothiols
increases, n = 3
All patients who received nitrite had an increase in S-nitrosothiols although this was not correlated with the change in plasma nitrite level
PMID 29175357 · one of two readings recorded this
Survival to hospital discharge
3 (75%) who received placebo was discharged alive
PMID 29175357 · one of two readings recorded this
Survival to hospital discharge
6 (86%) patients survived to discharge who received nitrite
PMID 29175357 · one of two readings recorded this
GFR
no effect, p = 0.012, n = 16
Acetazolamide | 83 [76;89]† | 84 [77;92] | 77 [70;83]* | 83 [75;91] | 83 [76;89] | 83 [76;89] | 85 [78;92] |.012
PMID 30241504 · one of two readings recorded this
GFR
no effect, p = 0.132, n = 16
Allopurinol | 99 [90;108] | 102 [93;112] | 97 [89;105] | 103 [94;112] | 98 [88;108] | 99 [91;107] | 102 [92;111] |.132
PMID 30241504 · one of two readings recorded this
GFR
no effect, p = 0.568, n = 16
Enalapril | 101 [92;110] | 104 [94;114] | 101 [94;108] | 104 [96;112] | 100 [91;109] | 102 [94;109] | 102 [94;110] |.568
PMID 30241504 · one of two readings recorded this
GFR
no effect, p = 0.027, n = 16
Placebo | 98 [90;105] | 104 [96;111] | 98 [91;105] | 105 [97;113]* | 101 [92;110] | 99 [93;106] | 100 [91;109] |.027
PMID 30241504 · one of two readings recorded this
Baseline 24-h urinary albumin excretion by pretreatment
no effect, p = 0.184, n = 16
U-albumin (mg/24 h) | 2.98 (1.25;4.75) | 2.02 (1.00;4.00) | 4.50 (1.32;8.25)* | 3.00 (2.25;4.75) |.184
PMID 30241504 · one of two readings recorded this
Baseline 24-h urinary sodium by pretreatment
decreases, p = 0.034, n = 16
U-Na (mmol/24 h) | 129 [107;151] | 135 [115;154] | 116 [98;134] | 101 [80;122]* |.034
PMID 30241504 · one of two readings recorded this
Baseline creatinine clearance by pretreatment (24-h urine)
decreases, p = 0.03, n = 16
CrCl (ml/min/1.73 m2) | 134 [120;148] | 137 [124;150] | 130 [117;142] | 116 [103;130]* |.030
PMID 30241504 · one of two readings recorded this
Baseline fractional excretion of potassium by pretreatment
increases, p = 0.001, n = 16
FEK (%) | 7.91 [6.71;9.11] | 7.55 [6.17;8.92] | 7.67 [6.48;8.85] | 11.6 [9.84;13.4]* | <.001
PMID 30241504 · one of two readings recorded this
Baseline plasma potassium by pretreatment
decreases, p = 0.001, n = 16
P-potassium (mmol/l) | 4.1 [4.0;4.1] | 4.0 [3.9;4.1] | 4.1 [4.0;4.2] | 3.6 [3.6;3.7]* | <.001
PMID 30241504 · one of two readings recorded this
Baseline plasma sodium by pretreatment
decreases, p = 0.025, n = 16
P-sodium (mmol/l) | 139 [138;139] | 138 [137;139] | 137 [137;138]* | 138 [137;139] |.025
PMID 30241504 · one of two readings recorded this
Baseline plasma total CO2 in venous blood by pretreatment
decreases, p = 0.001, n = 16
P-(vB)-total CO2 (mmol/l) | 25.1 [23.9;26.4] | 25.0 [24.0;26.0] | 24.4 [23.7;25.1] | 18.4 [17.4;19.3]* | <.001
PMID 30241504 · one of two readings recorded this
Baseline plasma urate by pretreatment
modulates, p = 0.001, n = 16
P-urate (mmol/l) | 0.29 [0.25;0.33] | 0.16 [0.13;0.20]* | 0.29 [0.25;0.33] | 0.34 [0.30;0.38]* | <.001
PMID 30241504 · one of two readings recorded this
Brachial diastolic BP change from baseline to last hour of infusion
decreases, p = 0.035, n = 16
Acetazolamide | 60 (58;63) | −1.58 (−3.04;-0.12) |.035
PMID 30241504 · one of two readings recorded this
Brachial diastolic BP change from baseline to last hour of infusion
no effect, p = 0.196, n = 16
Allopurinol | 60 (56;63) | −1.22 (−3.14;0.70) |.196
PMID 30241504 · one of two readings recorded this
Brachial diastolic BP change from baseline to last hour of infusion
no effect, p = 0.054, n = 16
Enalapril | 56 (53;59)† | −1.18 (−2.40;0.03) |.054
PMID 30241504 · one of two readings recorded this
Brachial diastolic BP change from baseline to last hour of infusion
no effect, p = 0.093, n = 16
Placebo | 60 (57;62) | −1.50 (−3.28;0.28) |.093
PMID 30241504 · one of two readings recorded this
Brachial MAP change from baseline to last hour of infusion
decreases, p = 0.006, n = 16
Acetazolamide | 78 (76;81) | −2.32 (−3.88;-0.76) |.006
PMID 30241504 · one of two readings recorded this
Brachial MAP change from baseline to last hour of infusion
decreases, p = 0.046, n = 16
Allopurinol | 78 (75;81) | −1.84 (−3.63;-0.04) |.046
PMID 30241504 · one of two readings recorded this
Brachial MAP change from baseline to last hour of infusion
decreases, p = 0.002, n = 16
Enalapril | 74 (72;77)† | −2.07 (−3.28;-0.86.) |.002
PMID 30241504 · one of two readings recorded this
Brachial MAP change from baseline to last hour of infusion
decreases, p = 0.018, n = 16
Placebo | 78 (76;81) | −1.88 (−3.39;-0.37) |.018
PMID 30241504 · one of two readings recorded this
brachial systolic blood pressure change from baseline to last hour of intravenous NaNO2 infusion (Omron 705IT oscillometric), after placebo or enzyme-inhibitor pretreatment; also FENa, GFR by 51Cr-EDTA, plasma NOx
decreases
Not recorded as a finding: the result compares a group with itself, not with a control
As shown in Table 5, brachial systolic BP was decreased, and heart rate increased during NaNO2 infusion regardless of pretreatment.
PMID 30241504 · one of two readings recorded this
brachial systolic blood pressure change from baseline to last hour of NaNO2 infusion (oscillometric, Omron 705IT), also FENa, GFR by 51Cr-EDTA, free water clearance, P-cGMP, P-NOx
decreases, n = 16
Not recorded as a finding: the result compares a group with itself, not with a control
As shown in Table 5, brachial systolic BP was decreased, and heart rate increased during NaNO2 infusion regardless of pretreatment.
PMID 30241504 · one of two readings recorded this
Brachial systolic BP change from baseline to last hour of infusion
decreases, p = 0.001, n = 16
Acetazolamide | 114 (111;118) | −3.79 (−5.85;-1.74) |.001
PMID 30241504 · one of two readings recorded this
Brachial systolic BP change from baseline to last hour of infusion
decreases, p = 0.006, n = 16
Allopurinol | 115 (111;119) | − 3.07 (−5.12;-1.01) |.006
PMID 30241504 · one of two readings recorded this
Brachial systolic BP change from baseline to last hour of infusion
decreases, p = 0.001, n = 16
Enalapril | 110 (107;114)† | −3.84 (−5.32;-2.35) | <.001
PMID 30241504 · one of two readings recorded this
Brachial systolic BP change from baseline to last hour of infusion
decreases, p = 0.007, n = 16
Placebo | 115 (111;119) | −2.63 (− 4.41;-0.85) |.007
PMID 30241504 · one of two readings recorded this
Central systolic BP change from baseline to last hour of infusion
no effect, p = 0.32, n = 16
Acetazolamide | 101 (90;112) | −2.69 (− 8.30;2.91) |.320
PMID 30241504 · one of two readings recorded this
Central systolic BP change from baseline to last hour of infusion
decreases, p = 0.047, n = 16
Allopurinol | 99 (91;107) | −4.51 (−8.95;-0.07) |.047
PMID 30241504 · one of two readings recorded this
Central systolic BP change from baseline to last hour of infusion
no effect, p = 0.053, n = 16
Enalapril | 97 (88;106) | −4.04 (−8.13;0.05) |.053
PMID 30241504 · one of two readings recorded this
Central systolic BP change from baseline to last hour of infusion
no effect, p = 0.528, n = 16
Placebo | 98 (89;106) | −1.38 (−6.03;3.26) |.528
PMID 30241504 · one of two readings recorded this
FENa
increases, p = 0.001, n = 16
Acetazolamide | 1.08 [0.86;1.29] | 1.25 [1.01;1.49] | 1.35 [1.08;1.63] | 1.29 [1.07;1.51] | 1.42 [1.15;1.69]* | 1.44 [1.17;1.71]* | 1.28 [1.05;1.52] |.001
PMID 30241504 · one of two readings recorded this
FENa
increases, p = 0.002, n = 16
Allopurinol | 1.36 [0.96;1.75] | 1.41 [1.05;1.76] | 1.52 [1.20;1.83] | 1.53 [1.22;1.83] | 1.66 [1.32;2.00]* | 1.69 [1.40;1.98]* | 1.59 [1.33;1.85] |.002
PMID 30241504 · one of two readings recorded this
FENa
increases, p = 0.001, n = 16
Enalapril | 1.15 [0.84;1.46] | 1.30 [1.01;1.60] | 1.42 [1.15;1.68]* | 1.45 [1.20;1.71]* | 1.59 [1.34;1.83]* | 1.56 [1.32;1.81]* | 1.52 [1.29;1.74]* | <.001
PMID 30241504 · one of two readings recorded this
FENa
increases, p = 0.001, n = 16
Placebo | 1.26 [1.05;1.47] | 1.26 [1.09;1.43] | 1.43 [1.25;1.62] | 1.38 [1.24;1.52] | 1.57 [1.36;1.78] | 1.53 [1.34;1.73] | 1.41 [1.26;1.56] |.001
PMID 30241504 · one of two readings recorded this
Free water clearance (CH2O)
decreases, p = 0.004, n = 16
Acetazolamide | 3.91 [2.80;5.01] | 1.99 [1.12;2.87] | 1.69 [0.93;2.46] | 1.63 [0.87;2.39]* | 2.60 [1.78;3.42] | 2.67 [1.78;3.55] | 2.60 [1.80;3.40] |.004
PMID 30241504 · one of two readings recorded this
Free water clearance (CH2O)
decreases, p = 0.011, n = 16
Allopurinol | 4.56 [3.64;5.48] | 3.05 [2.02;4.07] | 2.54 [1.82;3.27]* | 2.04 [0.98;3.10]* | 3.00 [2.11;3.90] | 3.06 [2.19;3.93] | 3.26 [2.40;4.12] |.011
PMID 30241504 · one of two readings recorded this
Free water clearance (CH2O)
decreases, p = 0.001, n = 16
Enalapril | 4.82 [3.70;5.94] | 3.57 [2.48;4.65] | 2.28 [1.26;3.29]* | 2.28 [1.48;3.08]* | 3.24 [2.59;3.89] | 2.23 [1.26;3.21]* | 2.67 [1.71;3.63] |.001
PMID 30241504 · one of two readings recorded this
Free water clearance (CH2O)
decreases, p = 0.001, n = 16
Placebo | 4.58 [3.66;5.50] | 2.87 [2.08;3.65] | 1.87 [1.36;2.38]* | 2.27 [1.46;3.08]* | 2.85 [2.11;3.59] | 2.64 [2.00;3.28]* | 2.85 [2.15;3.55]* | <.001
PMID 30241504 · one of two readings recorded this
Heart rate change from baseline to last hour of infusion
increases, p = 0.035, n = 16
Acetazolamide | 57 (53;61) | 1.30 (0.11;2.50)† |.035
PMID 30241504 · one of two readings recorded this
Heart rate change from baseline to last hour of infusion
increases, p = 0.037, n = 16
Allopurinol | 55 (52;59) | 1.70 (0.12;3.28)† |.037
PMID 30241504 · one of two readings recorded this
Heart rate change from baseline to last hour of infusion
increases, p = 0.002, n = 16
Enalapril | 56 (52;60) | 2.21 (0.97;3.45) |.002
PMID 30241504 · one of two readings recorded this
Heart rate change from baseline to last hour of infusion
increases, p = 0.001, n = 16
Placebo | 55 (52;58) | 3.37 (1.95;4.79) | <.001
PMID 30241504 · one of two readings recorded this
P-aldosterone
no effect, p = 0.826, n = 16
Acetazolamide | 184 (132;281)† | 178 (125;308) | 230 (110;352) |.826
PMID 30241504 · one of two readings recorded this